BACKGROUND: National data from the mid-1990s demonstrated that many eligible patients with HIV infection do not receive prophylaxis for opportunistic infections (OIs) and that racial and gender disparities existed in OI prophylaxis receipt. OBJECTIVE: We examined whether demographic disparities in use of OI prophylaxis persist in 2001 and if outpatient care is associated with OI prophylaxis utilization. RESEARCH DESIGN: Demographic, clinical, and pharmacy utilization data were collected from 10 U.S. HIV primary care sites in the HIV Research Network. SUBJECTS: This study consisted of adult patients (>or=18 years old) in longitudinal HIV primary care. MEASURES: Indications for Pneumocystis jiroveci pneumonia (PCP) or Mycobacterium avium complex (MAC) prophylaxis were 2 or more CD4 counts less than 200 or 50 cells/mm(3) during calendar year (CY) 2001, respectively. Using multivariate logistic regression, we examined demographic and clinical characteristics associated with receipt of PCP or MAC prophylaxis and the association of outpatient utilization with appropriate OI prophylaxis. RESULTS: Among eligible patients, 88.1% received PCP prophylaxis and 87.6% received MAC prophylaxis. Approximately 80% had 4 or more outpatient visits during CY 2001. Adjusting for care site, male gender (odds ratio [OR], 1.47), Medicare coverage (OR, 1.60), and having 4 or more outpatient visits in a year (OR, 2.34) were significantly associated with increased likelihood of PCP prophylaxis. Adjusting for care site, having 4 or more outpatient visits in a year (OR, 1.85) was associated with increased likelihood of receipt of MAC prophylaxis. There were no demographic or insurance characteristics associated with receipt of MAC prophylaxis. CONCLUSIONS: The overall prevalence of OI prophylaxis has increased since the mid-1990s, and previous racial and HIV risk factor disparities in receipt of OI prophylaxis have waned. Integration into the healthcare system is an important correlate of receiving OI prophylaxis.
BACKGROUND: National data from the mid-1990s demonstrated that many eligible patients with HIV infection do not receive prophylaxis for opportunistic infections (OIs) and that racial and gender disparities existed in OI prophylaxis receipt. OBJECTIVE: We examined whether demographic disparities in use of OI prophylaxis persist in 2001 and if outpatient care is associated with OI prophylaxis utilization. RESEARCH DESIGN: Demographic, clinical, and pharmacy utilization data were collected from 10 U.S. HIV primary care sites in the HIV Research Network. SUBJECTS: This study consisted of adult patients (>or=18 years old) in longitudinal HIV primary care. MEASURES: Indications for Pneumocystis jiroveci pneumonia (PCP) or Mycobacterium avium complex (MAC) prophylaxis were 2 or more CD4 counts less than 200 or 50 cells/mm(3) during calendar year (CY) 2001, respectively. Using multivariate logistic regression, we examined demographic and clinical characteristics associated with receipt of PCP or MAC prophylaxis and the association of outpatient utilization with appropriate OI prophylaxis. RESULTS: Among eligible patients, 88.1% received PCP prophylaxis and 87.6% received MAC prophylaxis. Approximately 80% had 4 or more outpatient visits during CY 2001. Adjusting for care site, male gender (odds ratio [OR], 1.47), Medicare coverage (OR, 1.60), and having 4 or more outpatient visits in a year (OR, 2.34) were significantly associated with increased likelihood of PCP prophylaxis. Adjusting for care site, having 4 or more outpatient visits in a year (OR, 1.85) was associated with increased likelihood of receipt of MAC prophylaxis. There were no demographic or insurance characteristics associated with receipt of MAC prophylaxis. CONCLUSIONS: The overall prevalence of OI prophylaxis has increased since the mid-1990s, and previous racial and HIV risk factor disparities in receipt of OI prophylaxis have waned. Integration into the healthcare system is an important correlate of receiving OI prophylaxis.
Authors: Baligh R Yehia; Kelly A Gebo; Perrin B Hicks; P Todd Korthuis; Richard D Moore; Michelande Ridore; William Christopher Mathews Journal: AIDS Patient Care STDS Date: 2008-12 Impact factor: 5.078
Authors: Geetanjali Chander; Seth Himelhoch; John A Fleishman; James Hellinger; Paul Gaist; Richard D Moore; Kelly A Gebo Journal: AIDS Care Date: 2009-05
Authors: Seth Himelhoch; Clayton H Brown; James Walkup; Geetanjali Chander; P Todd Korthius; Joseph Afful; Kelly A Gebo Journal: AIDS Date: 2009-08-24 Impact factor: 4.177
Authors: Christine U Oramasionwu; Jim M Koeller; Kenneth A Lawson; Carolyn M Brown; Gene D Morse; Christopher R Frei Journal: Med Care Date: 2012-11 Impact factor: 2.983
Authors: Seth Himelhoch; Geetanjali Chander; John A Fleishman; James Hellinger; Paul Gaist; Kelly A Gebo Journal: Gen Hosp Psychiatry Date: 2007 Nov-Dec Impact factor: 3.238
Authors: Baligh R Yehia; John A Fleishman; Perrin L Hicks; Michelande Ridore; Richard D Moore; Kelly A Gebo Journal: J Acquir Immune Defic Syndr Date: 2010-03 Impact factor: 3.731
Authors: Diana C Lemly; Bryan E Shepherd; Todd Hulgan; Peter Rebeiro; Samuel Stinnette; Robert B Blackwell; Sally Bebawy; Asghar Kheshti; Timothy R Sterling; Stephen P Raffanti Journal: J Infect Dis Date: 2009-04-01 Impact factor: 5.226
Authors: Seth Himelhoch; Joshua S Josephs; Geetanjali Chander; P Todd Korthuis; Kelly A Gebo Journal: Gen Hosp Psychiatry Date: 2009-08-27 Impact factor: 3.238